A Phase III Stratified, Remdomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immumogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-adjuvanted Comparator

Project Details

StatusFinished
Effective start/end date28/10/1431/10/19

Funding

  • Novartis Pharmaceuticals: $1,192,511.69

Keywords

  • Biotechnology & Drug Development, Infectious Diseases